Updated on 13 June 2013
The growing health care concern regarding death and disability from COPD will continue to affect Asia more than anywhere else in the world. For too long, the impact of COPD has been under-estimated due to lack of epidemiological data, misdiagnosis of lung disease, and inaccurate reporting of deaths. The mortality and morbidity burden of COPD is set to continue, particularly in Asia. The region is facing significant financial cost and lost productivity from COPD.
The priority is to improve treatment of COPD and to intervene in such a way as to increase survival. Improved treatment will emerge from ongoing and future clinical trials, for which Asian based research organizations are ideally placed. Increased survival however, will come from smoking cessation, the single most effective intervention.